Raymond James on Bristol-Myers Squibb Co. (BMY): 'we do not view the ZEPHYR data as signaling a risk to Cobenfy across indications'
Tweet Send to a Friend
Raymond James analyst Sean McCutcheon reiterated a Market Perform rating on Bristol-Myers Squibb Co. (NYSE: BMY).The analyst comments "In sum ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
